Supplier News: Euroapi, Cytiva, PCI Pharma & More
The latest from CDMOs, CMOs, and suppliers featuring Euroapi, Cytiva, PCI Pharma Services, Olon, and Pisgah Laboratories. Highlights below.
Chemicals/Chemical API Manufacturing
* Euroapi Investing $25 M for Biomass Boiler at French Facility
* Olon, University of Milan Create Scholarship for Photochemistry
Formulation Development/Drug Product Manufacturing
* Cytiva Opens Center of Excellence for Aseptic Filling Biz
* PCI Pharma Expanding High-Potency Solid Dosage Mfg
General
* Pisgah Labs Investing $55 M to Expand NC Facility
Chemicals/Chemical API Manufacturing
Euroapi Investing $25 M for Biomass Boiler at French Facility
Euroapi has initiated a EUR 24 million ($25 million) investment for the construction of a biomass boiler at its site in Seine-Maritime, France.
The 17-mega-watt equipment will use waste wood (Grade B) and is expected to produce 140,000 tons of steam per year to enable the company to cut its yearly fossil fuel CO2 emissions at the site by approximately 20,000 tons, or almost 76%, in 2026. It could also allow for the production of green electricity by using cogeneration technology to cover 10% of the needs onsite. The boiler is planned to be activated in 2025.
The Saint-Aubin-lès-Elbeuf sites is one of six Euroapi sites. It is specialized in large-scale fermentation and has downstream processing facilities. The new equipment at the site will also
allow the company to reduce the amount of energy required for the fermentation process behind the production of vitamin B12 that is produced at the site.
The French government is providing EUR 10.4 million ($10.6 million) to support the project as part of the country’s Relance plan, which aims to achieve carbon neutrality in the country by 2050.
Source: Euroapi
Olon, University of Milan Create Scholarship for Photochemistry
Olon, a Milan, Italy CDMO of active pharmaceutical ingredients (APIs), and the Department of Chemistry at the University of Milan have created a PhD-level scholarship in photochemistry for the development of new photochemistry-based processes in API production.
Olon’s co-funding of the scholarship will enable a PhD student from the University of Milan to work for three years on research topics to lead to the development of alternative processes for concrete industrial applications at Olon sites.
Source: Olon SpA
Formulation Development/Drug Product Manufacturing
Cytiva Opens Center of Excellence for Aseptic Filling Biz
Cytiva has opened a new 126,200-square-foot site in Burnaby, British Columbia, Canada, in the greater Vancouver area, to expand manufacturing capacity of aseptic-filling machines by over 200%. The machines, known as workcells, provide gloveless, robotic aseptic filling for final drug products into vials, syringes, and cartridges. The site will serve as a Center of Excellence for Cytiva’s aseptic-filling business and house R&D and services and serve as a base for the company’s global customer user group.
Transition to the new site has begun (as reported on July 27, 2022) with office and engineering personnel working from the new site and another location. Manufacturing will begin on the first workcell to be built at the newly opened site in September 2022. Production will be fully transferred over to the new site by the end of 2022.
Source: Cytiva
PCI Pharma Expanding High-Potency Solid Dosage Mfg
PCI Pharma Services, a CDMO of drug products and contract packager, has announced a multi-million-dollar expansion of its site in Tredegar, Wales, UK, to add two new facilities for manufacturing and packaging of solid oral-dose tablets and capsules for high-potency products.
The expansion will double large-scale processing capacity, including dispensing and fluid-bed granulation of high-potency solid-dose products at the commercial scale. In addition, there will be a new high-potency, multi-product packaging facility with primary and secondary blistering and bottling suites. The expansion is slated to be operational in the fall of 2022.
Source: PCI Pharma Services
General
Pisgah Labs Investing $55 M to Expand NC Facility
Pisgah Laboratories, a Pisgah Forest, North Carolina-based CDMO and part of Ipca Laboratories, a Mumbai, India-based CDMO of active pharmaceutical ingredients and drug products, is investing $55 million to expand a manufacturing product line at its facility in North Carolina, to add sterile injectables and liquid-filling operations. The expansion includes a new pilot manufacturing facility, a quality control laboratory, warehousing, and microbiological laboratories.
